Skip to main content
PMC home page
British Journal of Pharmacology and Chemotherapy logoLink to British Journal of Pharmacology and Chemotherapy
. 1961 Jun;16(3):296–308. doi: 10.1111/j.1476-5381.1961.tb01088.x

Tachyphylaxis to the anti-tetanus activity of some phenothiazine compounds

D R Laurence, R A Webster
PMCID: PMC1482022  PMID: 13759492

Abstract

Although chlorpromazine and acepromazine were the most potent suppressants of local tetanus induced in rabbits by intramuscular injection of the toxin of Cl. tetani, repeated injections lost their effect (tachyphylaxis) and sometimes even increased muscle activity, as did single large injections of either of the two drugs. As neither tachyphylaxis nor stimulation occurred in spinal animals, these effects might arise from an action in the brain-stem reticular formation on which chlorpromazine has been shown to have both inhibitory and excitatory effects. The possible cause of the tachyphylaxis is discussed. Evidence is advanced to support the view that tachyphylaxis can occur when chlorpromazine is used in the treatment of tetanus in man. Methotrimeprazine was more potent than chlorpromazine, but less prone to induce tachyphylaxis. These qualities rendered it more desirable for clinical use than the other two compounds.

Full text

PDF
296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADAMS E. B. Clinical trials in tetanus. Proc R Soc Med. 1958 Dec;51(12):1002–1006. [PubMed] [Google Scholar]
  2. ADAMS E. B., WRIGHT R., BERMAN E., LAURENCE D. R. Treatment of tetanus with chlorpromazine and barbiturates. Lancet. 1959 Apr 11;1(7076):755–757. doi: 10.1016/s0140-6736(59)91828-8. [DOI] [PubMed] [Google Scholar]
  3. BARR M. N. Effect of chlorpromazine on muscle spasm in human tetanus. Lancet. 1958 May 10;1(7028):991–993. doi: 10.1016/s0140-6736(58)91799-9. [DOI] [PubMed] [Google Scholar]
  4. CAHN J., GEORGES G., PIERRE R. Etude pharmacologique d'un nouveau dérivé de la phénothiazine, le 4632 RP ou méthopromazine. C R Seances Soc Biol Fil. 1957;151(12):2082–2084. [PubMed] [Google Scholar]
  5. DUNDEE J. W. Iatrogenic disease and anaesthesia. Br Med J. 1958 Jun 21;1(5085):1433–1438. doi: 10.1136/bmj.1.5085.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. GOLDMAN D. Treatment of psychotic states with chlorpromazine. J Am Med Assoc. 1955 Apr 9;157(15):1274–1278. doi: 10.1001/jama.1955.02950320004002. [DOI] [PubMed] [Google Scholar]
  7. HALL R. A., JACKSON R. B., SWAIN J. M. Neurotoxic reactions resulting from chlorpromazine administration. J Am Med Assoc. 1956 May 19;161(3):214–218. doi: 10.1001/jama.1956.02970030032008. [DOI] [PubMed] [Google Scholar]
  8. HIEBEL G., BONVALLET M., DELL P. Action de la chlorpromazine (Largactil 45 60 RP) au niveau du système nerveux central. Sem Hop. 1954 Jun 6;30(37):2346–2353. [PubMed] [Google Scholar]
  9. HIMWICH H. E. Psychopharmacologic drugs. Science. 1958 Jan 10;127(3289):59–72. doi: 10.1126/science.127.3289.59. [DOI] [PubMed] [Google Scholar]
  10. LAURENCE D. R., BERMAN E., SCRAGG J. N., ADAMS E. B. A clinical trial of chlorpromazine against barbiturates in tetanus. Lancet. 1958 May 10;1(7028):987–991. doi: 10.1016/s0140-6736(58)91798-7. [DOI] [PubMed] [Google Scholar]
  11. LAURENCE D. R., WEBSTER R. A. A method of assaying the anti-tetanus potency of drugs on experimental local tetanus in the rabbit. Br J Pharmacol Chemother. 1958 Sep;13(3):330–333. doi: 10.1111/j.1476-5381.1958.tb00913.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. LAURENCE D. R., WEBSTER R. A. The activity of a variety of chemical compounds against experimental tetanus. Br J Pharmacol Chemother. 1958 Sep;13(3):334–338. doi: 10.1111/j.1476-5381.1958.tb00914.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. MERCIER J., SCHMITT J., NAVARRO J., GAVEND M. R., GAVEND M. Etude pharmacologique d'un nouveau neuroplégique: le maléate acide de l'acétyl. 3-diméthylamino. 3'propyl-10 phénothiazine: 1522 CB. II. Action sur l'appareil cardio-vasculaire et le système nerveux végétatif; actions diverses; conclusions. Arch Int Pharmacodyn Ther. 1958 Jan 1;113(3-4):336–359. [PubMed] [Google Scholar]
  14. MOYER J. H., KINROSS-WRIGHT V., FINNEY R. M. Chlorpromazine as a therapeutic agent in clinical medicine. AMA Arch Intern Med. 1955 Feb;95(2):202–218. doi: 10.1001/archinte.1955.00250080024004. [DOI] [PubMed] [Google Scholar]
  15. PACKARD R. S., CARTMILL T. B., HENRY J. G. Management of severe tetanus; use of chlorpromazine in two patients. Br Med J. 1958 Jan 4;1(5061):16–20. doi: 10.1136/bmj.1.5061.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. RINALDI F., HIMWICH H. E. The site of action of antiparkinson drugs. Confin Neurol. 1955;15(4):209–224. doi: 10.1159/000105362. [DOI] [PubMed] [Google Scholar]
  17. ROTHBALLER A. B. Studies on the adrenaline-sensitive component of the reticular activating system. Electroencephalogr Clin Neurophysiol. 1956 Nov;8(4):603–621. doi: 10.1016/0013-4694(56)90084-0. [DOI] [PubMed] [Google Scholar]
  18. ROTH F. E., IRWIN S., ECKHARDT E., TABACHNICK I. I., GOVIER W. M. Perphenazine (trilafon), a new potent tranquilizer and antiemetic. II. General pharmacology. Arch Int Pharmacodyn Ther. 1959 Feb 1;118(3-4):375–383. [PubMed] [Google Scholar]
  19. SCHMITT J., MERCIER J., AUROUSSEAU M., HALLOT A., COMOY P. Sur une nouvelle série de composés neuroplégiques dérivés de la phénothiazine. C R Hebd Seances Acad Sci. 1957 Jan 7;244(2):255–258. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology and Chemotherapy are provided here courtesy of The British Pharmacological Society

RESOURCES